On 1/08/2016, Sun Trust Rbsn Humphrey released a statement about Ophthotech Corp (NASDAQ:OPHT) upped the target price from $0.00 to $100.00. At the time, this indicated a possible upside of 0%.

Having a price of $38.77, Ophthotech Corp (NASDAQ:OPHT) traded 0.00% even on the day. With the last stock price close down -88.84% from the two hundred day average, compared with the S&P 500 which has decreased -0.04% over the same time period. The company has recorded a 50-day moving average of $26.61 and a 200-day moving average of $45.60. 2,290,463 shares of OPHT traded hands, down from an average trading volume of 2,609,080

Performance Chart

With a total market value of $0, Ophthotech Corp has with a 52 week low of $4.53 and a 52 week high of $80.00 .

In addition to JPMorgan Chase & Co. reporting its target price, a total of 9 brokerages have released a report on Ophthotech Corp. The 12-month price target is $94.56 with 3 brokerages rating the stock a strong buy, 6 analysts rating the company a buy, one analyst rating the company a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the company a sell.

Brief Synopsis About Ophthotech Corp (NASDAQ:OPHT)

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.

The post JPMorgan Chase & Co. downgraded Ophthotech Corp (NASDAQ:OPHT) to Neutral in a statement released earlier today. appeared first on Octafinance.